Day: October 26, 2022

On December 28, 2000, Nichols, David E.; Grubbs, Russell A.; Mailman, Richard B. published a patent.Electric Literature of 58142-46-4 The title of the patent was Preparation of chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands. And the patent contained the following:

The title compounds I [R1, R2, R3 = H, alkyl, alkenyl; R8 = H, alkyl, phenoxy protecting group; X9 = H, halo, OR where R = H, alkyl, phenoxy protecting group, etc.; R4, R5, R6 = H, alkyl, Ph, halo, OR], potent dopamine receptor ligands, were prepared E.g., N-propyl-8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2-de]isoquinoline was prepared The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Electric Literature of 58142-46-4

The Article related to chromenoisoquinoline preparation dopamine receptor ligand, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Electric Literature of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 1, 2006, Yamada, Rintaro; Seto, Minoru published a patent.Application In Synthesis of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of diazaphenalene derivatives as myosin-control light chains phosphorylation inhibitors. And the patent contained the following:

Title compounds I [R1, R5-R8 = H, halo, hydroxy, etc.; X1···X2 = -CH(R2)CH(R3)-, -CH(R2)CH(R3)CH(R4)-, -C(R2):C(R3)-, etc.; R2-R4 = H, alkyl; A1, A11, A2, A21 = H, alkyl; Y = -CH(A3)-, -CH(A3)C(A4)(A41)-, single bond, etc.; A3, A4, A41 = H, alkyl; Z = hydroxy, -NR(A6)(A61); A6 = H, alkyl; A61 = H, alkyl, alkyl substituted with aryl group, etc.; further details on A1-A4 and A6 are given.] and salts thereof were prepared For example, reductive amination of tert-Bu 3-oxo-1-piperidinecarboxylate with 5-amino-4-vinylisoquinoline, e.g., prepared from 5-amino-4-bromoisoquinoline, followed by reaction with potassium tert-butoxide and treatment with HCl afforded compound II hydrochloride. In myosin-control light chains phosphorylation inhibition assays, compound II hydrochloride exhibited the IC50 value of ≤10 μM. Compounds I are claimed useful for the treatment of glaucoma, bronchial asthma, etc. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Application In Synthesis of 4-Bromo-5-nitroisoquinoline

The Article related to diazaphenalene preparation myosin control light chain phosphorylation inhibitor, glaucoma bronchial asthma treatment diazaphenalene preparation, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application In Synthesis of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 18, 1982, Kashdan, David S.; Schwartz, John A.; Rapoport, Henry published an article.Category: isoquinoline The title of the article was Synthesis of 1,2,3,4-tetrahydroisoquinolines. And the article contained the following:

Several aspects of 1,2,3,4-tetrahydroisoquinoline synthesis were examined An improved synthesis of 2-(m-methoxyphenyl)ethylamine (I) is reported. m-Anisaldehyde was treated with KCN and EtO2CCl to yield O-(ethoxycarbonyl)-3-methoxymandelonitrile. Hydrogenation gave I in 87% yield overall. Some observations were made regarding the reduction of 3,4-dihydroisoquinolines derived from the Bischler-Napieralski reaction. Amides II (R = R1 = MeO; R = H, R1 = OCH2Ph) were cyclized with POCl3 followed by reduction to the corresponding tetrahydroisoquinolines III, which were contaminated with 4% of IV (R = R1 = MeO) and 3% of IV (R = H, R1 = OCH2Ph), resp. Both IV (R = R1 = OMe) and IV (R = H, R1 = OCH2Ph) were independently synthesized by routes with general applicability to 8-alkoxy-1,2,3,4-tetrahydroisoquinolines. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Category: isoquinoline

The Article related to tetrahydroisoquinoline, hydroisoquinoline tetra, isoquinoline tetrahydro, phenethylbenzeneacetamide bischler napieralski cyclization, acetamide phenethylbenzene cyclization and other aspects.Category: isoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 25, 1975, Serban, Alexander published a patent.HPLC of Formula: 58142-46-4 The title of the patent was Isoquinolines. And the patent contained the following:

Substituted isoquinolines (I, where R1, R3, R4, R5, R6, R7 and R8 = H, alkyl, halo, nitro, amino, mono- and dialkyl substituted amino, mono- and diaryl substituted amino, acyl substituted amino, cyano, arylthio, alkylthio, and salts of these compounds) were prepared and are effective in controlling or eradicating undesired vegetation, insects, acarina, or fungi. Thus, 4-bromo-5-nitroisoquinoline (I) [58142-46-4], prepared by nitration of 4-bromoisoquinoline [1532-97-4], showed fungicidal activity. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).HPLC of Formula: 58142-46-4

The Article related to fungicide isoquinoline derivative, herbicide isoquinoline derivative, acaricide isoquinoline derivative, insecticide isoquinoline derivative, isoquinoline derivative pesticide and other aspects.HPLC of Formula: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 2, 2006, Fernandes, Prabhavathi B.; Mailman, Richard Bernard; Nichols, David Earl published a patent.Recommanded Product: 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of hexahydrobenzophenanthridines as dopamine receptor agonists for treatment of pulmonary edema. And the patent contained the following:

The title hexahydrobenzophenanthridines, hexahydrothienophenanthridines, phenylbenzodiazepines, chromenoisoquinolines, and naphthoisoquinolines with general formula of I and II [wherein X = H, OH, alkoxy, etc.; Y = O or (un)substituted CH2; R = H or alkyl; R1 = H, alkyl, acyl, etc.; R2-R4 = independently H, alkyl, Ph, halo, etc; R5-R7 = independently H, alkyl, or alkenyl; R8-R10 = independently H, OH, alkyl, Ph, halo, or alkoxy; R11 = H, alkyl, acyl, etc.; R12 = H, OH, alkoxy, etc.], or pharmaceutically acceptable salts thereof were prepared as dopamine receptor agonists for the treatment of pulmonary edema. For example, III was prepared in a multi-step synthesis. III showed agonistic activity with EC50 of 28±9 and 10±2 nM against human D1-like and D5 receptors, resp. Formulations as aerosols and dry powders, and methods for treating a patient having pulmonary edema are described. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 4-Bromo-5-nitroisoquinoline

The Article related to dopamine receptor agonist treatment pulmonary edema formulation human, preparation benzophenanthridine thienophenanthridine phenylbenzodiazepine chromenoisoquinoline naphthoisoquinoline and other aspects.Recommanded Product: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 25, 2002, Nichols, David Earl; Mailman, Richard Bernard; Huang, Xuemei published a patent.SDS of cas: 58142-46-4 The title of the patent was Method using D1 dopamine receptor agonists for treatment of dopamine-related dysfunction. And the patent contained the following:

The invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “”off-period””. The D1 agonist concentration is reduced during the “”off-period”” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises administering to a patient a full D1 agonist with a half-life of up to about 6 h periodically at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 h to obtain a second lower plasma concentration of agonist which results in suboptimal activation of D1 dopamine receptors for a period of time sufficient to prevent induction of tolerance. The dopamine D1 agonist is e.g. dinoxyline (preparation described). The methodol. of the invention may be used to treat e.g. Parkinson’s disease. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).SDS of cas: 58142-46-4

The Article related to dopamine related disease treatment d1 agonist tolerance prevention, dinoxyline preparation d1 agonist dopamine disease treatment, parkinson disease dopamine d1 agonist tolerance prevention and other aspects.SDS of cas: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 6, 1976, Serban, Alexander published a patent.Category: isoquinoline The title of the patent was 3-Chloro-5-acetamidoisoquinoline as a herbicide. And the patent contained the following:

Isoquinolines I (R = H, halo, NO2, NH2, AcNH, CN; R1 = H, Me, Bu, NO2, NH2, halo, CN, Me) and I.HR2 [R2 = Cl, CF3CO2, Br, iodide, C6Cl5O, 2,4-(O2N)2C6H3O, substituted phenoxy, ClCF2CO2, 2,4-(O2N)2C6H3CO2] (∼110 compounds), which possessed herbicidal, insecticidal, acaricidal, and fungicidal activity, were prepared Isoquinolines were nitrated by H2SO4-KNO3 to give nitro derivatives of I which were reduced to the amino derivatives; Sandmeyer or Schiemann reaction of aminoisoquinolines yielded halo derivatives of I. The title compound was a selective herbicide at 0.25-10 lb/acre against ipomoea, mustard, and sunflower in areas cultivated in wheat, peas, yegrass, or oats. I.HR2 (R = H, 5-Cl, 5-Br, 5-NO2; R1 = H, 1-Me; R2 = Cl, substituted phenoxy) controlled cabbage moth at 0.2% weight/vol and I.HR2 (R = H, 5-NO2; R1 = H, 3-Me; R2 = iodide, CF3CO2) at 1% weight/volume possessed ∼100% effective acaricidal activity against cattle tick nymphs and engorged adults. 4-Bromo-5-nitroisoquinoline possessed fungicidal activity against wheat powdery mildew at 0.008% weight/volume The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Category: isoquinoline

The Article related to isoquinoline nitro insecticide, haloisoquinoline herbicide, nitroalkylisoquinoline acaricide, bromonitroisoquinoline fungicide, chloroacetamidoisoquinoline herbicide, acetamidochloroisoquinoline herbicide and other aspects.Category: isoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On March 1, 2022, Zhou, Chao; Gan, Qi-Chao; Zhou, Tai-Ping; Lei, Tao; Ye, Chen; He, Xiao-Jun; Chen, Bin; Lu, Heng; Wan, Qian; Liao, Rong-Zhen; Tung, Chen-Ho; Wu, Li-Zhu published an article.Product Details of 1367744-24-8 The title of the article was Site-Selective N-1 and C-3 Heteroarylation of Indole with Heteroarylnitriles by Organocatalysis under Visible Light. And the article contained the following:

Site-selective N-1 and C-3 arylation of indole was sought after because of the prevalent application of arylindoles and the intricate reactivities associated with the multiple sites of the N-unsubstituted indole. Represented herein is the first regioselective heteroarylation of indole via a radical-radical cross-coupling by visible-light irradiation Steady and time-resolved spectroscopic and computational studies revealed that the hydrogen-bonding interaction of organic base and its conjugated acid, namely with indole and heteroarylnitrile, determined the reaction pathway, which underwent either proton-coupled electron-transfer or energy-transfer for the subsequent radical-radical cross-coupling, leading to the regioselective formation of C-3 and N-1 heteroarylation of indoles, resp. The parallel methodologies for regioisomeric N-1 and C-3 heteroaryl indoles with good functional group compatibility was applied to large-scale synthesis and late-stage derivatization of bioactive compounds under extremely mild reaction conditions. The experimental process involved the reaction of 5-Methylisoquinoline-1-carbonitrile(cas: 1367744-24-8).Product Details of 1367744-24-8

The Article related to indole isoquinolinecarbonitrile organocatalyst photochem regioselective heteroarylation, indolyl isoquinoline preparation, cross-coupling, heteroarylation, indoles, proton-coupled electron-transfer, radicals and other aspects.Product Details of 1367744-24-8

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 29, 2004, Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Chao, Jianhua; Yu, Younong; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Biju, Purakkattle J.; Nelson, Kingsley H.; Rokosz, Laura L.; Jakway, James P.; Lai, Gaifa; Wu, Minglang; Hecker, Evan A.; Lundell, Daniel; Fine, Jay S. published a patent.Application of 74904-29-3 The title of the patent was Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC-chemokine receptor ligands. And the patent contained the following:

Title compounds [I; A = (substituted) pyridylmethyl, thiazolylmethyl, benzofurylmethyl, isoxazolylmethyl, pyrazinylmethyl, triazolylmethyl, phenylalkyl, etc.; B = (substituted) Ph, benzotriazolyl, benzimidazolyl, imidazolyl, pyrazolyl, hydroxypyridinyl, thienyl, pyrrolyl, isothiazolyl, etc.], were prepared Thus, title compound (II) (preparation outlined) showed Ki = 0.8 nM in a CXCR2 SPA receptor binding assay. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Application of 74904-29-3

The Article related to aminocyclobutenedione preparation cxc chemokine receptor ligand, cyclobutenedione diamino preparation cxc chemokine receptor ligand, squaric acid amide preparation cancer pain inflammation contusion treatment and other aspects.Application of 74904-29-3

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

Ray Choudhury, Abhijnan; Mukherjee, Santanu published an article in 2016, the title of the article was Enantioselective dearomatization of isoquinolines by anion-binding catalysis en route to cyclic α-aminophosphonates.Name: 4-Bromo-5-nitroisoquinoline And the article contains the following content:

An enantioselective dearomatization of isoquinolines has been developed using chiral anion-binding catalysis. This transformation, catalyzed by a simple and easy to prepare tert-leucine-based thiourea derivative, makes use of silyl phosphite as a nucleophile and generates cyclic α-aminophosphonates. This is the first time asym. anion-binding catalysis has been applied to the synthesis of α-aminophosphonates. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Name: 4-Bromo-5-nitroisoquinoline

The Article related to enantioselective dearomatization isoquinoline anion binding catalysis, cyclic alpha aminophosphonate preparation crystal mol structure, tert leucine based thiourea catalyzed silyl phosphite reaction isoquinoline and other aspects.Name: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem